Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens. 2018;36(10):1953–2041. https://doi.org/10.1097/HJH.0000000000001940.

Article  CAS  Google Scholar 

•• Mancia G, Kjeldsen SE, Kreutz R, Pathak A, Grassi G, Esler M. Individualized beta-blocker treatment for high blood pressure dictated by medical comorbidities: indications beyond the 2018 European Society of Cardiology/European Society of Hypertension Guidelines. Hypertension. 2022;79(6):1153–66. https://doi.org/10.1161/HYPERTENSIONAHA.122.19020. This narrative review upgrades the role of beta-blockers in hypertension treatment and highlights the importance of individualized beta-blocker treatment in certain medical conditions.

Mancia G, Grassi G. The autonomic nervous system and hypertension. Circ Res. 2014;114:1804–14. https://doi.org/10.1161/CIRCRESAHA.114.302524.

Article  CAS  Google Scholar 

Agrawal A, Wenger NK. Hypertension during pregnancy. Curr Hypertens Rep. 2020;22(9):64. https://doi.org/10.1007/s11906-020-01070-0.

Article  Google Scholar 

Braunthal S, Brateanu A. Hypertension in pregnancy: pathophysiology and treatment. SAGE Open Med. 2019;7:2050312119843700. https://doi.org/10.1177/2050312119843700.

Article  Google Scholar 

Battarbee AN, Sinkey RG, Harper LM, Oparil S, Tita ATN. Chronic hypertension in pregnancy. Am J Obstet Gynecol. 2020;222(6):532–41. https://doi.org/10.1016/j.ajog.2019.11.1243.

Article  Google Scholar 

American College of Obstetricians and Gynecologists’ Committee on Practice Bulletins—Obstetrics. ACOG Practice Bulletin No. 203: Chronic Hypertension in Pregnancy. Obstet Gynecol. 2019;133(1):e26-e50. https://doi.org/10.1097/AOG.0000000000003020.

• Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, Blomström-Lundqvist C, Cifkovα R, De Bonis M, et al. 2018 ESC guidelines for the management of cardiovascular diseases during pregnancy. Eur Heart J. 2018;39(34):3165–241. https://doi.org/10.1093/eurheartj/ehy340. European guidelines for the management of cardiovascular diseases during pregnancy.

Bateman BT, Patorno E, Desai RJ, Seely EW, Mogun H, Maeda A, Fischer MA, Hernandez-Diaz S, Huybrechts KF. Late pregnancy β blocker exposure and risks of neonatal hypoglycemia and bradycardia. Pediatrics. 2016;138(3):e20160731. https://doi.org/10.1542/peds.2016-0731.

Tanaka K, Tanaka H, Kamiya C, Katsuragi S, Sawada M, Tsuritani M, et al. Beta-blockers and fetal growth restriction in pregnant women with cardiovascular disease. Circ J. 2016;80(10):2221–6. https://doi.org/10.1253/circj.CJ-15-0617.

Article  CAS  Google Scholar 

• Fitton CA, Steiner MFC, Aucott L, Pell JP, Mackay DF, Fleming M, McLay JS. In-utero exposure to antihypertensive medication and neonatal and child health outcomes: a systematic review. J Hypertens. 2017;35:2123–37. https://doi.org/10.1097/HJH.0000000000001456. This systematic review on adverse outcomes to the child associated with in utero exposure to antihypertensive medications demonstrates a paucity of relevant published high-quality studies, thus preventing any firm conclusions being drawn.

Al Khalaf SY, O'Reilly ÉJ, Barrett PM, B Leite DF, Pawley LC, McCarthy FP, et al. Impact of chronic hypertension and antihypertensive treatment on adverse perinatal outcomes: systematic review and meta-analysis. J Am Heart Assoc. 2021;10(9):e018494. https://doi.org/10.1161/JAHA.120.018494.

•• Garovic VD, Dechend R, Easterling T, Karumanchi SA, McMurtry Baird S, Magee LA, et al. American Heart Association Council on Hypertension; Hypertension in pregnancy: diagnosis, blood pressure goals, and pharmacotherapy: a scientific statement from the American Heart Association. Hypertension. 2022;79(2):e21–e41. https://doi.org/10.1161/HYP.0000000000000208. Relevant on the pathogenesis of hypertensive disorders of pregnancy and on the existing data on the safety of antihypertensives including beta-blockers in pregnancy.

Morton A. Physiological changes and cardiovascular investigations in pregnancy. Heart Lung Circ. 2021;30(1):e6–15. https://doi.org/10.1016/j.hlc.2020.10.001.

Article  Google Scholar 

de Haas S, Spaanderman MEA, van Kuijk SMJ, van Drongelen J, Mohseni Z, Jorissen L, et al. Adaptation of left ventricular diastolic function to pregnancy: a systematic review and meta-analysis. J Hypertens. 2021;39(10):1934–41. https://doi.org/10.1097/HJH.0000000000002886.

Article  CAS  Google Scholar 

ACOG Practice Bulletin No. 212: pregnancy and heart disease. Obstet Gynecol. 2019;133(5):e320–56. https://doi.org/10.1097/AOG.0000000000003243.

Article  Google Scholar 

Usselman CW, Wakefield PK, Skow RJ, Stickland MK, Chari RS, Julian CG, et al. Regulation of sympathetic nerve activity during the cold pressor test in normotensive pregnant and nonpregnant women. Hypertension. 2015;66:858–64. https://doi.org/10.1161/HYPERTENSIONAHA.115.05964.

Article  CAS  Google Scholar 

de Haas S, Ghossein-Doha C, van Kuijk SM, van Drongelen J, Spaanderman ME. Physiological adaptation of maternal plasma volume during pregnancy: a systematic review and meta-analysis. Ultrasound Obstet Gynecol. 2017;49:177–87. https://doi.org/10.1002/uog.17360.

Article  Google Scholar 

Phipps E, Prasanna D, Brima W, Jim B. Preeclampsia: updates in pathogenesis, definitions, and guidelines. Clin J Am SocNephrol. 2016;11(6):1102–13. https://doi.org/10.2215/CJN.12081115.

Article  CAS  Google Scholar 

• Ives CW, Sinkey R, Rajapreyar I, Tita ATN, Oparil S. Preeclampsia-pathophysiology and clinical presentations: JACC state-of-the-art review. J Am Coll Cardiol. 2020;76(14):1690–1702. https://doi.org/10.1016/j.jacc.2020.08.014. Overview about the pathophysiology of preeclampsia.

Rana S, Lemoine E, Granger JP, Karumanchi SA. Preeclampsia: pathophysiology, challenges, and perspectives. Circ Res. 2019;124(7):1094–112. https://doi.org/10.1161/CIRCRESAHA.118.313276.

Article  CAS  Google Scholar 

Tomimatsu T, Mimura K, Endo M, Kumasawa K, Kimura T. Pathophysiology of preeclampsia: an angiogenic imbalance and long-lasting systemic vascular dysfunction. Hypertens Res. 2017;40(4):305–10. https://doi.org/10.1038/hr.2016.152.

Article  CAS  Google Scholar 

Zeisler H, Llurba E, Chantraine F, Vatish M, Staff AC, Sennström M, et al. Predictive value of the sFlt-1:PlGF ratio in women with suspected preeclampsia. N Engl J Med. 2016;374:13–22. https://doi.org/10.1056/NEJMoa1414838.

Article  CAS  Google Scholar 

• de Haas S, Mulder E, Schartmann N, Mohseni Z, Abo Hasson F, Alsadah F, et al. Blood pressure adjustments throughout healthy and hypertensive pregnancy: a systematic review and meta-analysis. Pregnancy Hypertens. 2022;27:51–88. https://doi.org/10.1016/j.preghy.2021.12.004. Important study about gestational hypertensive complications and hemodynamic adjustments affecting blood pressure.

Guzik TJ, Touyz RM. Oxidative stress, inflammation, and vascular aging in hypertension. Hypertension. 2017;70(4):660–7. https://doi.org/10.1161/HYPERTENSIONAHA.117.07802.

Article  CAS  Google Scholar 

•• Binder NK, MacDonald TM, Beard SA, de Alwis N, Tong S, Kaitu'u-Lino TJ, Hannan NJ. Pre-clinical investigation of cardioprotective beta-blockers as a therapeutic strategy for preeclampsia. J Clin Med. 2021; 10(15):3384. https://doi.org/10.3390/jcm10153384. Important recent experimental evidence on the effects of beta-blockers in severe hypertension in pregnancy.

•• Woolston E, Tang Y, Azizi S, Kando I, Chamley L, Stone P, Chen Q. Comparison of the effects on maternal endothelial cell activation: an in vitro study of anti-hypertensive drugs clinically used in pre-eclampsia. J Hum Hypertens. 2022;36(2):192–200. https://doi.org/10.1038/s41371-021-00497-5. Important recent experimental evidence on the effects of beta-blockers in pre-eclampsia.

Magee LA, Namouz-Haddad S, Cao V, Koren G, von Dadelszen P. Labetalol for hypertension in pregnancy. Expert Opin Drug Saf. 2015;14(3):453–61. https://doi.org/10.1517/14740338.2015.998197.

Article  CAS  Google Scholar 

•• Bone JN, Sandhu A, Abalos ED, Khalil A, Singer J, Prasad S, et al. Oral Antihypertensives for nonsevere pregnancy hypertension: systematic review, network meta- and trial sequential analyses. Hypertension. 2022;79(3):614–28. https://doi.org/10.1161/HYPERTENSIONAHA.121.18415. Important study focused on analysis of antihypertensives consistently recommended in clinical guidelines in pregnancy, including beta-blockers and their effect in core maternal outcomes.

•• Mulder EG, Ghossein-Doha C, Cauffman E, Lopes van Balen VA, Schiffer VMMM, Alers RJ, et al. Preventing recurrent preeclampsia by tailored treatment of nonphysiologic hemodynamic adjustments to pregnancy. Hypertension. 2021;77(6):2045–53. https://doi.org/10.1161/HYPERTENSIONAHA.120.16502. Important study that indicates circulatory normalization of nonphysiological hemodynamic changes during pregnancy with labetalol halves the risk of recurrent preeclampsia, without disadvantageous effects on offspring outcome.

• Bellos I, Pergialiotis V, Papapanagiotou A, Loutradis D, Daskalakis G. Comparative efficacy and safety of oral antihypertensive agents in pregnant women with chronic hypertension: a network metaanalysis. Am J Obstet Gynecol. 2020;223(4):525–37. https://doi.org/10.1016/j.ajog.2020.03.016. Meta-analysis about the choice of antihypertensive treatment and the goal blood pressure during pregnancy.

Conçalves PV, Cavalli RC, da Cunha SP, Lanchote VL. Determination of pindolol enantiomers in amniotic fluid and breast milk by high-performance liquid chromatography: applications to pharmacokinetics in pregnant and lactating women. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;852:640–55. https://doi.org/10.1016/j.jchromb.2007.01.015.

Article  CAS  Google Scholar 

Abalos E, Duley L, Steyn DW, Gialdini C. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev. 2018;10(10):CD002252. https://doi.org/10.1002/14651858.CD002252.pub4.

Webster LM, Conti-Ramsden F, Seed PT, Webb AJ, Nelson-Piercy C, Chappell LC. Impact of antihypertensive treatment on maternal and perinatal outcomes in pregnancy complicated by chronic hypertension: a systematic review and meta-analysis. J Am Heart Assoc. 2017;6(5):e005526. https://doi.org/10.1161/JAHA.117.005526.

• Magee LA, CHIPS Study Group, von Dadelszen P, Singer J, Lee T, Rey E, et al. Do labetalol and methyldopa have different effects on pregnancy outcome? Analysis of data from the Control of Hypertension In Pregnancy Study (CHIPS) trial. BJOG. 2016;123:1143–51. https://doi.org/10.1111/1471-0528.13569. The study describes pregnancy outcomes, between methyldopa-treated and labetalol-treated women according to a target of “less tight” versus “tight” control of hypertension in pregnancy.

• Tita AT, Szychowski JM, Boggess K, Dugoff L, Sibai B, Lawrence K, et al. Chronic hypertension and pregnancy (CHAP) trial consortium. treatment for mild chronic hypertension during pregnancy. N Engl J Med. 2022;386(19):1781–92. https://doi.org/10.1056/NEJMoa2201295. The study showed, in pregnant women with mild chronic hypertension, treated with labetalol (in 60%) or nifedipine, reducing blood pressure of less than 140/90 mm Hg was associated with better pregnancy outcomes, than reserving treatment only for severe hypertension, with no increase in the risk of small-for-gestational-age birth weight.

• Awaludin A, Rahayu C, Daud NAA, Zakiyah N. Antihypertensive medications for severe hypertension in pregnancy: a systematic review and meta-analysis. Healthcare (Basel). 2022;10(2):325. https://doi.org/10.3390/healthcare10020325. Meta-analysis for the assessment of the effectiveness of antihypertensive drugs for severe hypertension during pregnancy. There was no difference in the risk of maternal and fetal outcomes, and adverse effects between the drugs.

Alavifard S, Chase R, Janoudi G, Chaumont A, Lanes A, Walker M, Gaudet L. First-line antihypertensive treatment for severe hypertension in pregnancy: a systematic review and network meta-analysis. Pregnancy Hypertens. 2019;8:179–87. https://doi.org/10.1016/j.preghy.2019.09.019.

Article  Google Scholar 

•• Al Khalaf S, Khashan AS, Chappell LC, O'Reilly ΙJ, McCarthy FP. Role of antihypertensive treatment and blood pressure control in the occurrence of adverse pregnancy outcomes: a population-based study of linked electronic health records. Hypertension. 2022;79(7):1548–58. https://doi.org/10.1161/HYPERTENSIONAHA.122.18920. A most recent study to examine the role of antihypertensive treatment in the association between chronic hypertension and adverse pregnancy outcomes.

Petersen KM, Jimenez-Solem E, Andersen TJ, Petersen M, Brødbæk K, Køber L, et al. β-blocker treatment during pregnancy and adverse pregnancy outcomes: a nationwide population-based cohort study. BMJ Open. 2012;2(4):e001185. https://doi.org/10.1136/bmjopen-2012-001185.

Xie RH, Guo Y, Krewski D, Mattison D, Walker MC, Nerenberg K, Wen SW. Beta-blockers increase the risk of being born small for gestational age or of being institutionalised during infancy. BJOG. 2014;121(9):1090–6. https://doi.org/10.1111/1471-0528.12678.

Article  Google Scholar 

Duan L, Ng A, Chen W, Spencer HT, Lee MS. Beta-blocker subtypes and risk of low birth weight in newborns. J Clin Hypertens (Greenwich). 2018;20(11):1603–9. https://doi.org/10.1111/jch.13397.

Article  CAS  Google Scholar 

• Fitton CA, Fleming M, Steiner MFC, Aucott L, Pell JP, Mackay DF, Mclay JS. In utero antihypertensive medication exposure and neonatal outcomes: a data linkage cohort study. Hypertension. 2020;75(3):628–33. https://doi.org/10.1161/HYPERTENSIONAHA.119.13802. This study supports that low birth weight and preterm birth may reflect increasing hypertension severity necessitating treatment in pregnancy.

•• Mulrenin IR, Garcia JE, Fashe MM, Loop MS, Daubert MA, Urrutia RP, Lee CR. The impact of pregnancy on antihypertensive drug metabolism and pharmacokinetics: current status and future directions. Expert Opin Drug Metab Toxicol. 2021;17(11):1261–79. https://doi.org/10.1080/17425255.2021.2002845. This study addresses information for more precise antihypertensive drug dosing strategies in pregnancy.

Abalos E, Duley L, Steyn DW. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev. 2014;(2):CD002252. https://doi.org/10.1002/14651858.CD002252.pub3.

Fisher SC, Van Zutphen AR, Romitti PA, Browne ML; National Birth Defects Prevention Study. Maternal hypertension, antihypertensive medication use, and small for gestational age births in the national birth defects prevention study, 1997–2011. Matern Child Health J. 2018;22(2):237–46. https://doi.org/10.1007/s10995-017-2395-8.

Yakoob MY, Bateman BT, Ho E, Hernandez-Diaz S, Franklin JM, Goodman JE, et al. The risk of congenital malformations associated with exposure to β-blockers early in pregnancy: a meta-analysis. Hypertension. 2013;62(2):375–81. https://doi.org/10.1161/HYPERTENSIONAHA.111.00833.

Article  CAS  Google Scholar 

Bergman JEH, Lutke LR, Gans ROB, Addor MC, Barisic I, Cavero-Carbonell C, et al. Beta-blocker use in pregnancy and risk of specific congenital anomalies: a European case-malformed control study. Drug Saf. 2018;41(4):415–27. https://doi.org/10.1007/s40264-017-0627-x.

Article  CAS  Google Scholar 

Bateman BT, Heide-Jørgensen U, Einarsdóttir K, Engeland A, Furu K, Gissler M, et al. β-blocker use in pregnancy and the risk for congenital malformations: an international cohort study. Ann Intern Med. 2018;169(10):665–73. https://doi.org/10.7326/M18-0338.

Article  Google Scholar 

• Wu Y, Yao JW, Xu LJ, Chen M, Wan L. Risk of congenital malformations in offspring of women using β-blockers during early pregnancy: an updated meta-analysis of observational studies. Br J Clin Pharmacol. 2021;87(3):806–15. https://doi.org/10.1111/bcp.14561. Recent meta-analysis of observational studies evaluating associations between maternal beta-blocker use and congenital malformations. Beta-blockers during early pregnancy does not appear to be associated with congenital malformations in offspring.

Magee LA, Khalil A, Kametas N, von Dadelszen P. Toward personalized management of chronic hypertension in pregnancy. Am J Obstet Gynecol. 2022;226(2S):S1196–210. https://doi.org/10.1016/j.ajog.2020.07.026.

Article  CAS  Google Scholar 

van Gelder MM, Van Bennekom CM, Louik C, Werler MM, Roeleveld N, Mitchell AA. Maternal hypertensive disorders, antihypertensive medication use, and the risk of birth defects: a case-control study. BJOG. 2015;122(7):1002–9. https://doi.org/10.1111/1471-0528.13138.

Article  Google Scholar 

Duan L, Ng A, Chen W, Spencer HT, Nguyen J, Shen AY, Lee MS. β-blocker exposure in pregnancy and risk of fetal cardiac anomalies. JAMA Intern Med. 2017;177(6):885–7. https://doi.org/10.1001/jamainternmed.2017.0608.

Article  Google Scholar 

Whelan A, Izewski J, Berkelhammer C, Walloch J, Kay HH. Labetalol-induced hepatotoxicity during pregnancy: a case report. AJP Rep. 2020;10:e210–2. https://doi.org/10.1055/s-0040-1713789.

Article  Google Scholar 

Tamirisa KP, Elkayam U, Briller JE, Mason PK, Pillarisetti J, Merchant FM, et al. Arrhythmias in pregnancy. JACC Clin Electrophysiol. 2022;8(1):120–35. https://doi.org/10.1016/j.jacep.2021.10.004.

Article  Google Scholar 

Hoeltzenbein M, Fietz AK, Kayser A, Zinke S, Meister R, Weber-Schoendorfer C, et al. Pregnancy outcome after first trimester exposure to bisoprolol: an observational cohort study. J Hypertens. 2018;36(10):2109–17. https://doi.org/10.1097/HJH.0000000000001818.

Article  CAS  Google Scholar 

• Kayser A, Beck E, Hoeltzenbein M, Zinke S, Meister R, Weber-Schoendorfer C, Schaefer C. Neonatal effects of intrauterine metoprolol/bisoprolol exposure during the second and third trimester: a cohort study with two comparison groups. J Hypertens. 2020;38(2):354–61. https://doi.org/10.1097/HJH.0000000000002256. In this observational study, metoprolol or bisoprolol may increase the risk of being born small-for-gestational-age, but serious neonatal symptoms are rare and with no statistical significance in comparison to nonhypertensive group.